AstraZeneca: Bronchial Diseases trials

The registry lists 17 Bronchial Diseases studies with AstraZeneca as lead sponsor. 0 are open to participants now and 16 have results posted.

Phase 2 2Phase 3 15(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With AsthmaCompletedNCT06644924Phase 2Results posted
• Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)CompletedNCT03688074Phase 2Results posted
• Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)CompletedNCT03186209Phase 3Results posted
• A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.CompletedNCT03170271Phase 3Results posted
• Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at HomeCompletedNCT02918071Phase 3Results posted
• A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic InflammationCompletedNCT02869438Phase 3Results posted
• A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 AgonistCompletedNCT02808819Phase 3Results posted
• Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at HomeCompletedNCT02417961Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent AsthmaCompletedNCT02322775Phase 3Results posted
• A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABACompletedNCT02258542Phase 3Results posted
• Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation HistoryCompletedNCT02155660Phase 3Results posted
• Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation HistoryCompletedNCT02138916Phase 3Results posted
• Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS TherapyCompletedNCT02075255Phase 3Results posted
• Efficacy and Safety Study of Benralizumab Added to Medium-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled AsthmaTerminatedNCT01947946Phase 3Results posted
• Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled AsthmaCompletedNCT01928771Phase 3Results posted
• Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 AgonistCompletedNCT01914757Phase 3Results posted
• Real Life Effectiveness in Asthma of Symbicort Single Inhaler TherapyCompletedNCT00319306Phase 3